Circulating tumor cells in precision medicine: challenges and opportunities.

Autor: Rupp B; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109,USA., Ball H; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109,USA., Wuchu F; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA., Nagrath D; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109,USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: dnagrath@umich.edu., Nagrath S; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109,USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: snagrath@umich.edu.
Jazyk: angličtina
Zdroj: Trends in pharmacological sciences [Trends Pharmacol Sci] 2022 May; Vol. 43 (5), pp. 378-391. Date of Electronic Publication: 2022 Mar 07.
DOI: 10.1016/j.tips.2022.02.005
Abstrakt: The mutational and phenotypic landscape of tumors is dynamic, requiring constant monitoring of cancer patients to provide the most up-to-date and effective care. Circulating tumor cells (CTCs) obtained via liquid biopsy can provide tumor DNA, RNA, and protein information that can aid in the diagnosis, prognosis, and treatment of patients. There have been many recent studies and advances in using CTC enumeration, characterization, and expansion to provide personalized cancer treatment, validating the benefit of using CTCs as a biomarker in standard of care procedures. In this paper, we aim to summarize these advances, their limitations, and suggest future areas of study necessary to bring CTC analysis to clinics.
Competing Interests: Declaration of interests S.N. is one of the named inventors on a patent for Microfluidic Labyrinth Technology granted to the University of Michigan. S.N is the co-founder of Labyrinth Biotech Inc. The funders and the company had no role/influence in the views expressed in this article or in the writing of the manuscript
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: